K 30H inhibitor - Newron Pharmaceuticals
Alternative Names: K-30H inhibitorLatest Information Update: 17 Aug 2007
At a glance
- Originator Newron Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 26 Mar 2004 Preclinical trials in Neurological disorders in Italy (unspecified route)